The pharmaceutical industry is undergoing a quiet but meaningful shift in how drugs are designed, manufactured, and delivered. Three-dimensional printing technology is moving out of the laboratory and into clinical development, enabling dosage forms with precise drug loading, programmable release kinetics, and patient-specific geometries that conventional tablet presses and capsule-filling machines simply cannot replicate. The urgency driving adoption is real: chronic disease populations are growing, rare disease patients need individualized dosing, and pediatric formulations demand flexibility that standard manufacturing cannot provide.
The Global 3D Printing Drugs Market was valued at $283.0 million in 2025 and is projected to reach $540.4 million by 2031, growing at a compound annual growth rate of 11.5% over the 2026–2031 period. That trajectory reflects sustained momentum across dosage form development, technology adoption, and regulatory engagement, not a short-lived spike in interest. The pace of clinical-stage activity—combined with the first commercial-scale FDA approval already on the market—signals a sector moving from proof-of-concept toward structured commercialization.
The companies shaping this market range from dedicated 3D printing pharmaceutical firms with growing clinical pipelines to large pharmaceutical multinationals investing in bioprinting and advanced drug delivery research. The following profiles cover ten key players whose strategies, platforms, and pipeline activities are defining the direction of the global 3D printing drugs market.
Tablets remain the dominant dosage form, generating $202.8 million in 2025 at an 11.5% CAGR, accounting for roughly 70% of oral dosage forms globally. The segment is anchored by the FDA-approved Spritam, the only commercially marketed 3D-printed drug, alongside a growing pipeline of candidates from Triastek including T19, T20, T21, T25, and T26. By technology, fused deposition modeling leads with $103.8 million in 2025 revenue, but inkjet printing is the fastest-growing technology at a 14.4% CAGR through 2031, valued for precision deposition and personalized dosing applications. Binder jet printing, the technology behind Spritam, holds $54.8 million and remains clinically significant for its ability to achieve high drug loading and rapid disintegration.
On the application side, neurological disorders represent the largest segment at $122.4 million in 2025, driven by Spritam's commercial presence and ongoing research into Parkinson's and Alzheimer's disease. Oncology is the fastest-growing application segment at a 15.1% CAGR, fueled by the need for personalized therapies, targeted delivery, and multidrug combinations. Geographically, North America leads with 42.3% of the market, supported by FDA regulatory infrastructure and the presence of Aprecia Pharmaceuticals and Triastek. Asia-Pacific is the fastest-growing region at 13.1% CAGR through 2031, propelled by Triastek's planned large-scale manufacturing facility in Nanjing and its cross-border collaboration with BioNTech on RNA therapeutics.
• Headquarters: Mason, Ohio, U.S.
• Founded: 2003
• Focus: 3D-printed pharmaceutical products, rapid disintegration formulations, alternative drug delivery methods
Aprecia holds a singular position in this market: it is the company behind Spritam, the world's first and only FDA-approved 3D-printed drug manufactured at commercial scale using binder jet printing. Spritam's high drug loading capacity of up to 1,000 mg and rapid-disintegration profile make it particularly suitable for patients with swallowing difficulties. In 2024, the FDA approved an expanded route of administration via nasogastric and gastrostomy tubes. Aprecia is also partnering with Apprentice.io on AI-powered manufacturing and with Battelle under the DARPA/HHS EQUIP-A-Pharma program for agile, point-of-need drug production.
• Headquarters: Shanghai, China
• Founded: 2015
• Focus: 3D printing drugs, programmable drug delivery via MED platform, oral solid dosage form development, RNA-based therapeutics for oral delivery
Triastek has built the most advanced clinical pipeline in the 3D printing drugs space, with candidates T19, T20, T20G, T21, T25, T26, and D23 advancing through FDA and China NMPA regulatory pathways. Its proprietary Melt Extrusion Deposition platform enables chronotherapeutic, site-specific, and sustained-release dosage forms. The company entered a platform licensing agreement with BioNTech for oral RNA therapeutics and is developing what is described as the world's largest 3D-printed pharmaceutical manufacturing facility in Nanjing, targeting up to 300 million tablets annually.
• Focus: Pharmaceutical 3D printing platforms (M3DIMAKER), personalized medicine and point-of-care drug manufacturing, 3D-printed oral dosage forms, pharma inks, AI for pharmaceutical development
FABRX operates across the full technology stack for pharmaceutical 3D printing—hardware, formulation inks, software, and AI-assisted development. Its M3DIMAKER platform enables on-demand production of printlets in hospital and pharmacy settings. In 2025, the company collaborated with Pfizer on dose-flexible crystalline solid-dispersion tablets for first-in-human studies. In 2026, FABRX launched a preheater system enabling production of over 10,000 capsules per day and integrated HEPA filtration into M3DIMAKER 2 to support safe handling of high-risk oncology drugs in cleanroom environments.
• Focus: SPID 3D screen-printing platform, complex oral dosage form development, modified-release formulations, patented generic drug development
Laxxon Medical's proprietary SPID (Screen Printed Innovative Drug) technology enables precisely controlled, multi-phase drug release in complex oral dosage forms. Its lead candidate, LXM.5, a Levodopa/Carbidopa formulation for Parkinson's disease, demonstrated bioavailability over 380% higher than conventional therapy in clinical data reported in 2025. A collaboration with Adare Pharma Solutions supports cGMP-compliant, scalable manufacturing. The company is also developing a modified-release Enobosarm tablet and an oral GLP-1 therapy formulation, positioning itself for a transition from R&D into commercial production.
• Headquarters: San Francisco, California, U.S.
• Founded: 2016
• Focus: Robotic and automated pharmaceutical manufacturing systems, cell and gene therapy manufacturing, 3D-printed multi-component capsule systems, GMP-compatible manufacturing platforms
Multiply Labs approaches the 3D printing drugs ecosystem from the manufacturing automation angle, integrating robotics into pharmaceutical production to achieve consistency, throughput, and GMP compliance. The company is developing systems for cell and gene therapy manufacturing and multi-component capsule production, with an emphasis on decentralized and on-demand pharmaceutical manufacturing. Its pilots evaluate robotic automation for cell-based therapies, and it is expanding partnerships to integrate robotic systems with existing bioprocessing equipment, positioning itself as a technology provider rather than a drug developer.
• Headquarters: Helsinki, Finland
• Founded: 2021
• Focus: 3D printing of personalized medicines, pharmaceutical inks development, drug compounding automation software, 3D printer systems for hospitals and pharmacies
CurifyLabs targets the pharmacy and hospital end of the personalized medicine supply chain, offering an integrated system combining 3D printers, pharmaceutical inks, and automation software for on-demand drug compounding. In 2023, the company launched GMP-produced pharmaceutical inks enabling production of patient-specific medicines at the point of care. Operating primarily in Europe and the U.S., CurifyLabs represents the decentralized manufacturing model that health systems are increasingly exploring to reduce dependence on centralized supply chains and support individualized dosing.
• Headquarters: Darmstadt, Germany
• Founded: 1668
• Revenue: $23,866.8 million (FY2025)
• Employees: 62,461
• Focus: Life science, healthcare, electronics
Merck KGaA contributes to the 3D printing drugs market through its formulation expertise and materials capabilities, including excipients, bioinks, and biomaterials used in drug delivery research. In 2026, the company announced a cooperation agreement with AMCM to advance GMP-compliant 3D-printed tablet manufacturing for clinical trials, with plans to scale toward commercial manufacturing. Using powder bed fusion technology and integrating proprietary excipient capabilities, Merck KGaA is working to establish flexible, small-batch tablet production that meets evolving regulatory standards in Europe.
• Headquarters: Cambridge, U.K.
• Founded: 1999
• Revenue: $58,739 million (FY2025)
• Employees: 95,100
• Focus: Oncology, biopharmaceuticals, drug discovery, preclinical development, 3D bioprinting research
AstraZeneca's involvement in 3D printing centers on drug discovery and preclinical development rather than commercial dosage form manufacturing. The company has developed 3D bioprinted liver organoids in collaboration with CELLINK, creating human tissue environments that replicate cardiovascular, renal, and metabolic disease conditions for drug safety and efficacy testing. This supports AstraZeneca's broader goal of improving preclinical screening fidelity and reducing reliance on animal models. In FY2025, the company reported 8% revenue growth (constant exchange rate) driven by its oncology and biopharmaceutical portfolios.
• Headquarters: London, U.K.
• Founded: 1999
• Revenue: $43,069.4 million (FY2025)
• Employees: 66,800
• Focus: General medicines, specialty medicines, HIV, oncology, respiratory, immunology and inflammation, 3D-printed pharmaceuticals (R&D), bioprinting and 3D tissue models (R&D)
GSK is applying 3D printing and bioprinting technologies within its R&D function, focusing on personalized medicines, advanced drug delivery systems, and 3D human tissue models for drug testing and toxicity studies. The company increased R&D spending by 11% in 2025 to advance its pipeline in oncology and specialty medicines, with bioprinting supporting its ambition to reduce dependence on animal testing. GSK's position reflects how large pharmaceutical companies are embedding additive manufacturing into early-stage development workflows ahead of any commercial-scale implementation.
• Headquarters: New Brunswick, New Jersey, U.S.
• Founded: 1886
• Revenue: $94.2 billion (FY2025)
• Employees: 138,200
• Focus: Innovative medicine (pharmaceuticals), medical technologies, 3D printing in drug development
Johnson & Johnson is exploring 3D printing and bioprinting as tools for personalized medicines, customized dosage forms, and improved drug delivery systems within its pharmaceutical R&D operations. Through collaborations with technology and bioprinting partners, the company is developing 3D-printed tissue models to enhance accuracy and efficiency in drug testing. Commercial 3D-printed drugs have not yet been launched by J&J, but its scale and cross-sector expertise in both pharmaceuticals and medical technologies position it as a significant future participant as the market matures.
The Global 3D Printing Drugs Market is at a genuine inflection point. The regulatory foundation laid by Spritam's FDA approval in 2015 has given way to a decade of clinical-stage activity, expanded manufacturing investment, and accelerating technology development. Companies like Triastek and Aprecia are pushing directly toward commercial-scale 3D-printed drug production, while platform specialists such as FABRX, CurifyLabs, and Laxxon Medical are building the enabling infrastructure—inks, printers, software, and manufacturing agreements—that the broader industry will rely on.
Large pharmaceutical companies including AstraZeneca, GSK, Merck KGaA, and Johnson & Johnson are embedding 3D printing and bioprinting into their R&D workflows, signaling that the technology's role in drug development is becoming standard practice rather than experimental. As oncology, neurological disorders, and cardiovascular applications continue to drive demand, the competitive landscape will be shaped by whoever can most effectively bridge precision dosage form design with GMP-compliant, scalable manufacturing. That challenge is where the next phase of this market's growth will be won or lost.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.